Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Evaluation of Changes of Serum Hepatitis B Surface Antigen from a Different Perspective.

[Dynamic changes of serum HBsAg levels at different grades of liver inflammation and stages of hepatic fibrosis in HBeAg-negative hepatitis B patients].

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

A Perspective of the Relationship of Serum HBV DNA and HBsAg Apportioned by the Same Hepatic Parenchyma Cell Volume with Inflammation in the Natural History of Chronic Hepatitis B.

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

[Dynamic Expression Profile of HBsAg According to Hepatic Parenchyma Cells' Volume at Different Liver Fibrosis Stages in the Immune Clearance Phase].

The Clinical Value of Serum Hepatic Parenchyma Cell Volume-Normalized Hepatitis B Surface Antigen Levels in Hepatitis B E Antigen -Positive and -Negative Chronic Hepatitis B Patients

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Dynamic Changes of HBsAg Expression by the Same Hepatic Parenchyma Cells Volume at Different Liver Fibrosis Stages in Immune Escape Phase

Serum HBeAg and HBV DNA Levels Are Not Always Proportional and Only High Levels of HBeAg Most Likely Correlate with High Levels of HBV DNA: A Community-Based Study.

HBsAg Quantitative Value in Different Stages of Hepatitis B Virus Infection and Its Correlations with Serum HBV DNA and Age

Clinical Implications of Hepatitis B Surface Antigen Quantitation in the Natural History of Chronic Hepatitis B Virus Infection.

Role of Serum Hepatitis B Virus Marker Quantitation to Differentiate Natural History

Serum HBV DNA loads apportioned by the same hepatic parenchyma cell volume and the liver inflammation grades in HBeAg-negative chronic hepatitis B

Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients

Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection

Quantitative Analyses of Intrahepatic HBV Cccdna and Serum HBsAg in 54 Patients with Chronic Hepatitis B

Effect of Serum Hepatitis B Surface Antigen Levels on Predicting the Clinical Outcomes of Chronic Hepatitis B Infection: A Meta‐analysis

Decline Of Serum Hbv Dna And No Change Apportioned By The Same Hepatic Parenchyma Cell Volume From Hepatic Fibrosis Stage 1 To Stage 4 During The Natural History Of Chronic Hepatitis B